Rezolute (RZLT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RZLT Rezolute

Watchlist

5.250
+0.030+0.57%

Close Sep 13 16:00 ET

5.071
-0.179-3.40%

Post 20:01 ET

290.62MMarket Cap-4605P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | BTIG Maintains Buy on Rezolute, Raises Price Target to $15
BenzingaSep 10 12:19 ET
Rezolute's Drug Pipeline Progress and FDA Hold Lift Propel Buy Rating and Increased Price Target
TipRanksSep 10 10:35 ET · Ratings
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $7 to $15
Moomoo NewsSep 10 09:00 ET · Ratings
Rezolute Analyst Ratings
BenzingaSep 9 13:24 ET · Ratings
Rezolute Buy Rating Affirmed: RZ358 Clinical Advancements and Strong Market Potential
TipRanksSep 9 12:25 ET · Ratings
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
BenzingaSep 9 10:41 ET

Comments

Jaguar8

Sep 9 06:33

NEWS

$Rezolute (RZLT.US)$
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA has lifted partial clinical holds on RZ358 (ersodetug), their potential treatment for hypoglycemia caused by congenital hyperinsulinism (HI). This allows the company to include U.S. participants in their ongoing global Phase 3 sunRIZE study. Rezolute plans to begin U.S. enrollm...

Trytosaveabit

Sep 9 06:31

News

$Rezolute (RZLT.US)$ Reuters· 1 min ago
FDA Lifts Partial Clinical Holds on Rz358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

steven smith38

Aug 5 06:40

$Apple (AAPL.US)$ Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

steven smith38

Aug 5 06:40

Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Trytosaveabit

Aug 5 06:37

Update

$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

RZLT Rezolute

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target